
Aardvark Therapeutics, Inc. Common Stock (AARD) Market Cap
Aardvark Therapeutics, Inc. Common Stock has a market capitalization of $120.6M.
Financials based on reported quarter end 2025-12-31
Price: $5.53
โฒ 0.16 (2.98%)
Market Cap: 120.64M
NASDAQ ยท time unavailable
CEO: Tien-Li Lee
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2025-02-13
Website: https://aardvarktherapeutics.com
Aardvark Therapeutics, Inc. Common Stock (AARD) - Company Information
Market Cap: 120.64M ยท Sector: Healthcare
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Analyst Sentiment
Based on 8 ratings
Analyst 1Y Forecast: $26.00
Average target (based on 2 sources)
Consensus Price Target
Low
$6
Median
$35
High
$47
Average
$29
Potential Upside: 430.4%
Price & Moving Averages
Related Companies in Healthcare

TREACE MEDICAL CONCEPTS INC (TMCI)
Healthcare
$0.12B
Mkt Cap

CARDIFF ONCOLOGY INC (CRDF)
Healthcare
$0.12B
Mkt Cap

JOURNEY MEDICAL CORP (DERM)
Healthcare
$0.12B
Mkt Cap

JOINT CORP (JYNT)
Healthcare
$0.12B
Mkt Cap

DEFINITIVE HEALTHCARE CORP CLASS A (DH)
Healthcare
$0.12B
Mkt Cap

AVITA MEDICAL INC (RCEL)
Healthcare
$0.12B
Mkt Cap
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"AARD reported revenue of $0 and a net loss of $17.6M (EPS: -$0.81) for the most recent period ended 2025-12-31. With revenue at zero in the dataset, net margin is not meaningfully measurable; however, profitability appears weak given the negative bottom line. Free cash flow was also negative at -$14.4M, driven by negative operating cash flow (-$14.4M), with no capex recorded and no dividends paid. On the balance sheet, the company had $117.2M in total assets versus $10.5M in total liabilities, resulting in $106.6M of equity. Net debt is -$46.6M, indicating net cash rather than leverage, which supports near-term balance sheet resilience. From a valuation and investor-return perspective, the stock price (around $3.54) is down sharply, with a -61.1% 1-year change and -73.2% YTD decline. With no dividends and no buyback data provided, shareholder value creation is primarily reflected through capital depreciation rather than cash returns. Analyst price targets are widely dispersed (low $6 to high $47; consensus $28), reflecting uncertainty around future operating turnaround and cash generation."
Revenue Growth
Revenue is shown as $0 for the period, preventing assessment of growth and signaling materially limited top-line contribution (based on the provided dataset).
Profitability
Net income is -$18.0M with EPS of -$0.81, indicating ongoing losses and no evidence of margin expansion in the reported period.
Cash Flow Quality
Free cash flow is -$14.4M, driven by negative operating cash flow; no dividends and no capex are reported, implying cash burn rather than self-funding.
Leverage & Balance Sheet
Net debt is -$46.6M (net cash position) and equity is large relative to liabilities, supporting financial resilience despite operating cash outflows.
Shareholder Returns
Total shareholder value is negative primarily due to weak capital appreciation: -61.1% over 1 year and -73.2% YTD; dividends are zero and no buybacks are provided.
Analyst Sentiment & Valuation
Valuation context is limited by missing standard valuation metrics; analyst targets are highly dispersed (low $6 to high $47), suggesting uncertainty about forward prospects.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.